What is Tesamorelin?
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the 44 amino acids of human GHRH with a trans-3-hexenoic acid modification at the N-terminus. This modification provides enhanced stability and potency compared to native GHRH.
Tesamorelin is unique among GHRH analogs as it has FDA approval (Egrifta®) for treating HIV-associated lipodystrophy, making it one of the most thoroughly studied peptides in its class.
The 2mg vial provides 1-2 days of research at standard doses.
Quick Reference
| Parameter | Value |
|---|---|
| Peptide Amount | 2mg |
| Recommended BAC Water | 2mL |
| Resulting Concentration | 1mg/mL (1000mcg/mL) |
| Typical Research Dose | 1-2mg |
| Frequency | Once daily |
| Research Duration | 12-26 weeks |
Tesamorelin vs Other GHRH Analogs
| Peptide | Potency | Half-life | FDA Approved |
|---|---|---|---|
| Tesamorelin | High | ~30-40 min | Yes |
| Sermorelin | Moderate | ~15-20 min | Previously |
| CJC-1295 no DAC | Moderate | ~30 min | No |
| CJC-1295 DAC | High | ~8 days | No |
Reconstitution Guide
Materials Needed
- Tesamorelin 2mg lyophilized vial
- Bacteriostatic water (BAC water)
- Insulin syringes (U-100, 29-31 gauge)
- Alcohol swabs
- Sharps container
Step-by-Step Instructions
-
Prepare workspace — Clean area, wash hands thoroughly.
-
Clean vial stoppers — Wipe with alcohol swabs. Let dry.
-
Draw BAC water — Draw 2mL of bacteriostatic water.
-
Add to peptide vial — Inject slowly down the inside wall.
-
Dissolve — Tesamorelin may take 5-10 minutes. Gently swirl.
-
Verify — Solution should be clear and colorless.
-
Label and refrigerate — Store immediately.
Alternative Reconstitution
| BAC Water | Concentration | Best For |
|---|---|---|
| 2mL | 1mg/mL | Standard - easy math |
| 1mL | 2mg/mL | Smaller volumes |
Dosage Protocol
Concentration Calculations
With 2mg peptide in 2mL BAC water:
- Concentration: 1mg/mL = 1000mcg/mL
- Per unit (U-100 syringe): 10mcg per unit
Common Dose Calculations
| Desired Dose | Draw Volume | Syringe Units |
|---|---|---|
| 1mg | 1.00mL | 100 units |
| 1.5mg | 1.50mL | Use 2 draws |
| 2mg | 2.00mL | Full vial |
Doses Per Vial
At 1mg/mL concentration (2mL total = 2mg):
| Daily Dose | Doses Per Vial | Duration |
|---|---|---|
| 1mg | 2 doses | 2 days |
| 2mg | 1 dose | 1 day |
Note: The 2mg vial is small. Most extended research protocols require multiple vials or larger sizes.
Suggested Research Protocols
Protocol A: Standard (FDA Dosing)
- Dose: 2mg
- Frequency: Once daily
- Duration: 12-26 weeks
- Note: Based on approved medical use
Protocol B: Conservative
- Dose: 1mg
- Frequency: Once daily
- Duration: 12-26 weeks
Protocol C: With GHRP
- Tesamorelin: 1-2mg
- Ipamorelin: 100-200mcg
- Frequency: Once daily (together)
- Duration: 12+ weeks
Timing Considerations
Optimal timing:
- Morning on empty stomach
- Alternatively: Before bed
Important:
- Take 30+ minutes before food
- Consistent timing recommended
- Avoid high-fat meals near injection time
Injection Guide
Subcutaneous Administration
- Clean injection site with alcohol swab
- Pinch skin fold at abdomen
- Insert needle at 90° angle
- Inject slowly (larger volume)
- Wait 10 seconds before withdrawing
- Apply gentle pressure
Site Selection
Recommended: Abdomen (rotate between areas)
- Left lower abdomen
- Right lower abdomen
- Avoid navel area (2-inch radius)
Storage Requirements
Lyophilized
- Temperature: -20°C or colder
- Duration: 2+ years
Reconstituted
- Temperature: 2-8°C
- Duration: 3-4 weeks
- Note: Use promptly; Tesamorelin is somewhat sensitive
Research Considerations
Mechanism of Action
Tesamorelin works through:
- GHRH receptor activation — Pituitary stimulation
- Pulsatile GH release — Maintains natural rhythm
- IGF-1 elevation — Secondary to GH increase
- Metabolic effects — Studied effects on visceral fat
Key Research Findings
Clinical studies have demonstrated:
- Significant reduction in visceral adipose tissue
- Improved trunk fat distribution
- IGF-1 elevation without supraphysiological levels
- Relatively selective GH release
Tesamorelin Research Areas
| Area | Evidence Level |
|---|---|
| Visceral fat reduction | Strong (FDA approved) |
| Lipodystrophy | Strong (FDA approved) |
| Liver fat reduction | Moderate |
| Cognitive function | Emerging |
| Body composition | Moderate |
Why Choose Tesamorelin
Advantages:
- FDA-approved (most clinical data)
- Once-daily dosing
- Specific effects on visceral fat
- Relatively clean GH release
- Well-characterized safety profile
Considerations:
- Higher dose requirement (1-2mg vs mcg)
- More expensive per treatment
- Requires consistent daily use
- Larger injection volumes
Stacking Options
Tesamorelin + Ipamorelin
- GHRH + GHRP synergy
- Enhanced GH release
- May allow lower Tesamorelin dose
Tesamorelin alone
- Sufficient for most GH goals
- Clean protocol
- FDA-studied as monotherapy
Sourcing for Research
Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.
Scientific References
- Falutz J, et al. “Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV.” N Engl J Med. 2007;357(23):2359-2370.
- Stanley TL, et al. “Effects of Tesamorelin on Hepatic Transcriptome in HIV-Associated NAFLD.” J Clin Endocrinol Metab. 2020;105(8):e2801-2811.
- Dhillon S. “Tesamorelin: A Review of Its Use in the Management of HIV-Associated Lipodystrophy.” Drugs. 2011;71(8):1071-1091.
Last updated: December 23, 2025
Disclaimer: This information is for educational and research purposes only. Tesamorelin is available as an FDA-approved prescription medication (Egrifta®). Research-grade peptides are not intended for human consumption.